Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club

Inward Investment
Return to: PBR Home | Inward Investment | News
Search Refinements

Inward Investment News

View news from other Pharmaceutical sectors:
91-105 of 412 results
CytoDyn to purchase Progenics PRO 140 anti-HIV drug
31 July 2012 | By PBR Staff Writer
CytoDyn has entered into an agreement to purchase Progenics Pharmaceuticals' proprietary humanized monoclonal antibody HIV viral-entry inhibitor drug candidate, PRO 140, for $3.5m.
Inward Investment > News
Boehringer purchases rights to Funxional's FX125L compound
24 July 2012 | By PBR Staff Writer
Boehringer Ingelheim and Funxional Therapeutics have signed an agreement under which Boehringer will acquire the global rights to Funxional's FX125L compound and somatotaxin program.
Inward Investment > News
Synergy, Callisto sign definitive merger agreement
23 July 2012 | By PBR Staff Writer
Callisto Pharmaceuticals will merge with Synergy Pharmaceuticals following a definitive merger agreement between both the companies.
Inward Investment > News
GlaxoSmithKline to takeover HGS
17 July 2012 | By PBR Staff Writer
GlaxoSmithKline (GSK) has signed a definitive agreement to acquire Human Genome Sciences (HGS) for $14.25 per share in cash.
Inward Investment > News
Amgen acquires KAI pharmaceuticals
06 July 2012 | By PBR Staff Writer
US based pharmaceutical company, Amgen has acquired KAI Pharmaceuticals.
Inward Investment > News
Genstar Capital takes over ERT
05 July 2012 | By PBR Staff Writer
Genstar Capital has completed the acquisition of the ERT in a take-private transaction valued at approximately $400m.
Inward Investment > News
Bristol-Myers Squibb to take over Amylin pharmaceuticals
02 July 2012 | By PBR Staff Writer
Bristol-Myers Squibb will acquire Amylin for $31.00 per share in cash, pursuant to a cash tender offer and second step merger, or a total buying price nearing $5.3bn.
Inward Investment > News
Cornerstone buys EKR Therapeutics
28 June 2012 | By PBR Staff Writer
Cornerstone Therapeutics has acquired a privately-held specialty pharmaceutical company focused on the acute-care hospital setting, EKR Therapeutics.
Inward Investment > News
InterMune completes sale of Actimmune
21 June 2012 | By PBR Staff Writer
InterMune has completed divestiture of Actimmune (interferon gamma-1b) to Vidara Therapeutics, a part of an international specialty pharmaceutical group of companies with operations in Ireland and the US.
Inward Investment > News
AstraZeneca takes over Ardea Biosciences
21 June 2012 | By PBR Staff Writer
AstraZeneca, a biopharmaceutical company, has completed the purchase of a US-based biotechnology company, Ardea Biosciences.
Inward Investment > News
Valeant Pharmaceuticals to acquire OraPharma
18 June 2012 | By PBR Staff Writer
Valeant Pharmaceuticals has signed an agreement to buy OraPharma, an oral health company, from Water Street Healthcare Partners.
Inward Investment > News
Amgen takes over more than 99% of MN Pharmaceuticals shares
13 June 2012 | By PBR Staff Writer
Amgen has completed the acquisition of more than 99% of the shares of Mustafa Nevzat Pharmaceuticals (MN Pharmaceuticals), a privately held Turkish company.
Inward Investment > News
Takeda America takes over URL Pharma
06 June 2012 | By PBR Staff Writer
Takeda America Holdings, a wholly owned subsidiary of Takeda Pharmaceutical Company, has acquired URL Pharma for an upfront payment of $800m.
Inward Investment > News
Eli Lilly opens new diabetes-focused R&D center in China
01 June 2012 | By PBR Staff Writer
Eli Lilly and Company has officially opened the Lilly China Research and Development Center (LCRDC), a diabetes-focused research and development center in Shanghai, China.
Inward Investment > News
InterMune signs deal with Vidara Therapeutics to divest Actimmune
22 May 2012 | By PBR Staff Writer
InterMune has signed a definitive agreement with Vidara Therapeutics International (Vidara) to sell its rights to Actimmune (interferon gamma-1b) in $55m cash transaction and a two-year royalty stream.
Inward Investment > News
91-105 of 412 results